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Abstract
Background and aims:Thalassemia patients are predisposed to septicemia due to iron overload. The iron chelators have a potential role in 
the treatment of septicemia. This study was conducted to investigate the in vitro effect of iron chelators, deferoxamine (DFO), deferiprone 
(DFP), and deferasirox (DFS) on the growth of effective bacteria (Staphylococcus aureus, Yersinia enterocolitica, and Pseudomonas 
aeruginosa) and their synergistic effect with each other and antibiotics. 
Materials and Methods: Five bacterial strains were incubated in the presence of seven chelators in Mueller Hinton agar and the number 
of colonies was recorded for each sample. Antibiotic discs were placed in the plates. Susceptibility to antibiotics was assessed by disc 
diffusion method (Kirby-Bauer test) and also the zone inhibition around the disc was measured in mm after incubating the relevant plate 
at 37°C for a day. 
Results: The growth of all the studied bacteria increased in the presence of iron and was inhibited in the presence of different chelators. 
Chelators and antibiotics had synergistic effects on growth inhibition of Escherichia coli, S. aureus, and P. aeruginosa in culture medium, 
while the growth inhibition of Y. enterocolitica was seen in the presence of deferiprone and deferasirox combination. 
Conclusion: Chelators in combination with antibiotics exert synergistic effects on growth inhibition of prevalent bacteria (except for Y. 
enterocolitica).
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Introduction 
Thalassemia is a genetic blood disorder which is 
characterized by abnormality in the synthesis of 
hemoglobin beta chain and ranges from severe to 
asymptomatic anemia (1). The prevalence of thalassemia 
varies worldwide. In Iran, 8000 pregnancies per year are 
estimated to be at risk of having babies with thalassemia 
(2). Major Thalassemia is considered as a severe form of 
thalassemia which is manifested within the first two years 
of life and the affected patients should regularly undergo 
red blood cell transfusion (1). Blood transfusion in these 
patients leads to complications of iron overload with high 
morbidity and mortality if left untreated (3, 4). 
Iron overload in thalassemia patients could cause bone 
disorders, endocrine gland disorders (delayed growth, 
sexual maturation disorders, diabetes mellitus, and 
failure of thyroid, parathyroid, and adrenal glands), heart 
problems, and cirrhosis (1,5,6). One of the conditions 
that could cause death of thalassemia patients is infectious 
diseases and subsequent septicemia (7-9). In these patients, 
increase in blood ferritin, repeated venous catheterizations, 
and splenectomy are considered as major risk factors for 
septicemia. In addition, these patients are predisposed to 
infection with gram-positive and -negative bacteria (10, 
11).
Although thalassemia declines the quality of life among 
the affected patients (12), the treatment with different 
iron chelators enhances life expectancy, decreases iron 
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overload-associated complications, and promotes health 
in them (13,4). Some studies have indicated that iron 
chelators have a potential role in the treatment of septicemia 
(15). Although iron overload in thalassemia patients 
is an independent predictive factor for infection, some 
investigations have demonstrated that bacterial response 
to iron overload in the body could vary. Accordingly, iron 
overload causes an increase in the growth of some bacteria 
and a decrease in the growth of some others. In addition, 
the type of chelators could contribute greatly to bacterial 
growth (16,17). It is necessary to investigate new classes 
of iron chelators recently developed for the treatment of 
various diseases including thalassemia. It is because their 
antibacterial activities may be greater than their chelation-
related ones (18).
The findings on the potential viability of iron chelators 
as therapeutic agents against various bacteria have been 
inconsistent. Moreover, as bacterial resistance against 
antibiotics has increased and the synergistic effect of iron 
chelators and antibiotics has not yet been investigated, this 
study is conducted to investigate the in vitro effect of iron 
chelators, deferoxamine (DFO) (Desferal), deferiprone 
(DFP), and deferasirox (DFS) on the growth of the 
effective bacteria and their synergistic effect alongside 
each other and antibiotics in thalassemia patients with 
septicemia (Escherichia coli, Staphylococcus epidermidis, 
Staphylococcus aureus, Yersinia enterocolitica, and 
Pseudomonas aeruginosa).
Materials and Methods
In this experimental laboratory study, five bacterial samples 
including E. coli ATCC: 27922, S. aureus ATCC: 27923, 
S. epidermidis ATCC 12228, Y. enterocolitica ATCC 
33669, and P. aeruginosa ATCC: 27853were obtained from 
Scientific and Industrial Research Co, Tehran, Iran. Then, 
the samples were cultured on iron-containing and non-iron-
containing media using standard bacteriologic methods 
(19). Iron-containing media were divided into two groups. 
Then, two sets of chelators were individually added as 
follows: Group 1 without chelators and group 2 containing 
3 plates with only one chelator including DFO, DFS, and 
DFP (Iran Daru Co), as well as 4 plates with a combination 
of Desferal + DFS, Desferal + DFP, DFP+DFS and Desferal 
+ DFP + DFS. Then, the sensitivity of cultured bacteria to 
some common antibiotics in iron-containing media with 
and without chelators was consequently detected (Figures 
1, 2). The details of our procedures were as follows: For the 
samples with iron, 0.025 g ferric iron chloride (equivalent 
to 150 µM ferric chloride) was mixed with Mueller-Hinton 
agar (Merck), left at 121°C, and autoclaved for 15 minutes. 
After the temperature declined to 50°C, the chelators of 
interest at 100 µM/L concentration were introduced into 
the medium of interest per molecular mass (g) of each 
chelator (20,21). Therefore, 0.56 g/L DFO, 0.37 g/L DFS, 
and 0.14 g/L DFP were added to the culture media. 
Bacterial samples in the tubes containing saline and 0.5 
McFarland standard media were separated using 10 μL 
sampler while being adjacent to flame, cultured in the plates 
containing 20 cc Mueller-Hinton agar, and incubated at 
37°C overnight. The bacterial growth was measured by the 
number of developed colonies and reported in CFU/mL 
(19).
Then, the five bacteria (E. coli, S. epidermidis, S. aureus, 
Y. enterocolitica, and P. aeruginosa) were inoculated on the 
plates containing Mueller-Hinton base medium using 
sterile swab and incubated at 37°C overnight. The bacterial 
growth was reported in CFU/mL.
In the plates containing Mueller-Hinton base medium 
and iron, the effective antibiotic discs (Gen Fanavaran 
Tehran, Iran) at doses of interest were placed (22). In 
such a way, 30 µg vancomycin disc (Biomerieux, Sweden) 
could be used for S. aureus, 30 µg cefazoline disc for S. 
Figure 1. Flowchart of Study Design
Figure 2. Antibiotic Disc Diffusion (DFO, DFS and DFP). 
Abbreviations: DFO, deferoxamine; DFS, deferasirox; DFP, 
deferiprone.
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epidermidis, 10 µg gentamicin disc for Y. enterocolitica, 10 
µg gentamicin disc for E. coli, and 30 µg amikacin as well 
as 30 µg ceftazidime discs separately for P. aeruginosa. The 
zone of growth inhibition (in mm) was recorded after the 
incubation of the relevant plate at 37°C overnight (19).
Afterwards, the bacteria and the Mueller-Hinton base 
medium alongside the iron were added to the culture media 
and the chelators, both as single and combined, which were 
also added to antibiotic discs incubated at 37°C overnight. 
The zone of growth inhibition was reported in mm and 
classified as susceptible, intermediate, and resistant with 
reference to the Clinical and Laboratory Standards Institute 
(CLSI) (22) (Table 1). 
Results
The growth of all bacteria increased in Mueller-Hinton 
agar in the presence of iron. The growth of E. coli, S. aureus, 
S. epidermidis, Y. enterocolitica, and P. aeruginosa increased 
in the plate containing Mueller-Hinton agar and antibiotic 
disc with addition of iron (Table 2). Overall, the growth of 
all bacteria was inhibited in the presence of the chelators. 
The growth inhibition was found different only for E. 
coli. In the presence of various chelators (both alone and 
combined), the growth of E. coli (in CFU) was inhibited 
differently. The lowest positive effect of the chelators on 
E. coli growth inhibition was derived for DFS+DFP as 
compared with others (Table 2). No difference was seen in 
the number of grown colonies of E. coli between the plates 
with chelators and the ones without them. In addition, 
increase in the zone of growth inhibition of E. coli was seen 
in the presence of the antibiotics and chelators, that is, they 
had a synergistic effect on the growth inhibition of E. coli 
(Table 2).
According to the guidelines of CLSI, E. coli was 
susceptible to gentamicin with 14-mmzone of growth 
inhibition. In the presence of various chelators (both 
single and combined), E. coli showed high susceptibility 
to gentamicin. The growth of S. aureus was inhibited in 
the presence of different chelators, with no difference in 
inhibition among the chelators (Table 2). No difference was 
seen in the number of grown colonies of S. aureus between 
the plates with chelators and the ones without them. The 
increase in the zone of growth inhibition of S. aureus was 
seen in presence of antibiotics and chelators (Table 2). 
Based on CLSI guidelines, S. aureus was susceptible to the 
used antibiotic with 13-mm zone of growth inhibition. 
In the presence of various chelators and antibiotics (both 
single and combined) in the culture medium, the zone of 
growth inhibition increased.
The growth of S. epidermidis was inhibited in presence 
of different chelators, with no significant difference in 
inhibition among the chelators (Table 2). No difference 
was seen in the number of grown colonies of S. epidermidis 
between the plates with chelators and the ones without 
them. The increase in the zone of growth inhibition of S. 
epidermidis means the inhibition of bacterial growth in 
presence of chelators and antibiotics (Table 2).
According to CLSI guidelines, S. epidermidis was 
susceptible to cefazolin with 18-mmzone of growth 
inhibition. In the presence of various chelators (single and 
combined), the zone of growth inhibition increased, and 
therefore S. epidermidis growth was inhibited. The growth 
of Y. enterocolitica was inhibited in the presence of different 
chelators, with the highest inhibition in the presence of 
DFP and DFS (Table 2). No difference was seen in the 
number of grown colonies of Y. enterocolitica between the 
plates containing chelators and the ones without them.
The growth of Y. enterocolitica was inhibited mostly in 
the presence of DFP+DFS+ gentamicin (the highest zone of 
growth inhibition). The growth of Y. enterocolitica did not 
change in the presence of DFS and gentamicin disc, and 
the zone of growth inhibition of Y. enterocolitica decreased 
in the presence of gentamicin and other chelators (Desferal, 
DFP, Desferal + DFS, Desferal +DFP, and Desferal + 
DFP+DFS), which represents the increased growth of Y. 
enterocolitica (Table 2).
According to CLSI, Y. enterocolitica was susceptible to 
gentamicin with 25-mmzone of growth inhibition. In the 
presence of various chelators and antibiotics (both single 
and combined), the zone of growth inhibition increased, 
and therefore Y. enterocolitica growth was inhibited (Table 
2). No difference was seen in the number of grown colonies 
of S. epidermidis between the plates with chelators and 
the ones without them. The growth of P. aeruginosa was 
inhibited in the presence of chelators (except for DFP) 
and amikacin, which was illustrated as increase in zone of 
growth inhibition in Table 2. The zone of growth inhibition 
or inhibition of P. aeruginosa growth was highest in the 
presence of various combinations of chelators. Based on 
CLSI, P. aeruginosa was susceptible to the used antibiotic 
with 30-mmzone of growth inhibition. In the presence of 
various chelators (both single and combined), the zone of 
growth inhibition increased, and therefore P. aeruginosa 
growth was inhibited in the plate with the antibiotic, 
chelator, and iron.
Table 1. Susceptibility of bacteria to antibiotics by zone of growth inhibition
Bacteria and Antibiotic Resistance Intermediate Susceptible
Escherichia coli-gentamicin 12 ≤  13-14 15 ≥ 
Staphylococcus aureus-
vancomycin
6 ≤  6-7 7 ≥ 
Staphylococcus epidermidis-
cefazoline
14 ≤  15-17 18 ≥ 
Yersinia enterocolitica-
gentamicin
12 ≤  13-14 15 ≥ 
Pseudomonas aeruginosa-
amikacin
14 ≤  15-16 17 ≥ 
Pseudomonas aeruginosa-
ceftazidime
14 ≤  15-17 17 ≥ 
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Pseudomonas aeruginosa zone of growth inhibition 
increased in the presence of ceftazidime and different 
chelators, with the highest increase in the presence of 
Desferal and the lowest zone of growth inhibition or the 
highest bacterial growth in the presence of Desferal + DFS 
(Table 2). Based on CLSI, P. aeruginosa was susceptible to 
ceftazidime with 28-mmzone of growth inhibition. In the 
presence of various chelators plus ceftazidime, the zone of 
growth inhibition increased, and therefore bacterial growth 
was inhibited.
Discussion
In the present study, the growth of all bacteria in the 
culture medium and also antibiotic disc increased as iron 
was introduced. Clearly, studies have demonstrated that 
many pathogenic bacteria need external sources of iron for 
growth and survival (23-30). Iron as a cofactor contributes 
mainly to many of the reactions of oxygen transmission, 
metabolism, and production of energy and nucleic acid. 
Therefore, the growth of bacteria is likely to increase as 
iron is added. This study indicated that the growth of all 
bacteria was inhibited in the presence of different chelators, 
but the inhibition was different only for E. coli.
Thompson et al conducted a study on the antibacterial 
effect of iron chelators on nosocomial pathogens and 
demonstrated that DFP in tissue culture medium inhibited 
the growth of E. coli and other bacteria under study, 
while DFO did not do so (26). Because DFO is likely to 
provide iron to the bacteria by the receptor of their cognate 
siderophore, these findings are predictable. On the other 
hand, other mutant species of bacteria need 0.05 mm iron 
for growth (31), and therefore resistant species should be 
further studied.
For S. aureus, the growth was inhibited in the presence 
of various chelators in the present study. In a study on 
the effect of DFP on in vitro growth of staphylococci, 
the growth of S. aureus was inhibited in the presence of 
DFP, which could be considered for the patients with 
iron overload (32). The results of the study conducted 
by Thompson et al were consistent with the ones of the 
present study. Moreover, DFO had no inhibitory effect on 
S. aureus growth because it facilitates the transmission of 
iron for bacterial growth (26). S. aureus is actively involved 
in the absorption of iron in iron-limited environments 
by producing siderophore (33), which probably leads to 
inconsistency of the response to DFO. The findings of 
another study indicated that the reason for the increased 
growth of S. aureus in the presence of Desferal is the use 
of DFO by the bacteria in ATP-binding cassette transport 
system for further use of environmental iron (34).
For S. epidermidis, the growth was inhibited in the 
presence of various types of chelators, with no remarkable 
difference among them. In a study on the effects of DFP 
and DFO on the in vitro growth of various staphylococci, 
Kim and Shin demonstrated that S. epidermidis was not 
able to absorb iron and growth in the medium containing 
the transferrin-binding iron (non-free iron). Moreover, 
the growth of S. epidermidis was inhibited in the presence 
of Desferal. S. epidermidis also responded to DFP in the 
culture medium which acted as an inhibitory agent for its 
growth (32). In another study, the growth of S. epidermidis 
was inhibited in the presence of the chelator and the 
inhibitory effect was removed when iron was introduced 
(35). Anyway, S. epidermidis exhibits a better growth in the 
patients with increased blood iron (36), and therefore this 
finding could not be considered surprising. On the other 
hand, S. epidermidis could be susceptible to the chelator 
and gene variations probably have not yet been developed 
to give this property to S. epidermidis.
For Y. enterocolitica, the growth was inhibited when 
different types of chelators were added to Mueller Hinton 
agar and iron. In addition, Y. enterocolitica showed 
different responses to growth inhibition in different media.
The zone of growth inhibition of Y. enterocolitica 
Table 2. Comparison of number of colony-forming units and zone of growth inhibition for different bacteria in medium with and without iron 
Without iron With iron
Bacterial growth (CFU/
mL)
Zone of growth inhibition with antibiotic
(mm)
Bacterial growth 
(CFU/mL)
Zone of growth inhibition 
with antibiotic (mm)
Escherichia coli 30×103 20 45×103 14
Staphylococcus aureus 24×103 15 32×103 13
Staphylococcus epidermidis 2.3×104 30 a 3×104 25 a
Yersinia enterocolitica 9×103 28 14.5×103 25
Pseudomonas aeruginosa 
(with amikacin)
18×103 31 a 23×103 30 a
Pseudomonas aeruginosa 
(with ceftazidime)
18×103 32a 23×103 28 a
a susceptible (according to the Clinical and Laboratory Standards Institute).
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decreased in the presence of gentamicin and other chelators 
(Desferal, DFP, Desferal + DFS, Desferal + DFP, and 
Desferal + DFP + DFS). This means that the growth of 
Y. enterocolitica increased, which could be explained by 
the factors associated with doses of chelators, the type of 
antibiotic, or virulent properties of the used strain. DFP 
inhibited the growth of Y. enterocolitica by decreasing iron 
availability, which is consistent with other studies (35). The 
study conducted by Chan et al demonstrated that DFO 
could increase the risk of infection with Y. enterocolitica, 
while DFP did not contribute positively to both in vivo 
and in vitro growth of Y. enterocolitica (17). These findings 
on Y. enterocolitica in different media could be explained 
by the variety of doses of chelators and siderophore-
producing property of Y. enterocolitica (37). Yersiniabactin 
is a siderophore which has been initially detached from Y. 
enterocolitica. In addition to having the ability to absorb 
iron, this siderophore can bind to copper to prevent 
bacterial death (38).
In the present study, the growth of P. aeruginosa was 
inhibited in the presence of chelators (except for DFP) 
and amikacin. The study conducted by van Asbeck et al 
also indicated that DFO exerted inhibitory effect on P. 
aeruginosa growth in the absence of iron (35). Moreover, 
the study conducted by Thompson et al indicated that DFP 
had an inhibitory effect on the growth of P. aeruginosa, but 
DFO did not (26). The siderophore in P. aeruginosa, called 
pyoverdine, could help to explain the difference in response 
to chelators (39).
In the present study, the growth of E. coli, S. epidermidis, 
S. aureus, and P. aeruginosa was inhibited in the presence of 
used antibiotic discs and different chelators. The growth of 
Y. enterocolitica was inhibited in the presence of gentamicin 
and combination of DFP and DFS. van Asbeck et al and 
Hartzen et al also found that DFO and antibiotics could 
have a synergistic effect on growth inhibition of bacteria 
(35,40). Notably, the in vivo combination of chelators 
and antibiotics should be used cautiously, which deserves 
detailed in-depth studies. 
Overall, iron chelators prevent bacterial growth by 
preventing iron absorption, but the difference in the effect 
on different bacteria among the chelators could be due to 
the difference in the interaction of the type of siderophore 
in the cell wall, the type of chelating drug, and the mutant 
strains of the bacteria.
Conclusion
Due to the affinity of iron with various bacteria and the 
positive effect of chelators through the decrease in iron 
availability and the synergistic effect with antibiotics, it 
seems logical to recommend that chelators should be used 
for thalassemia patients with bacterial septicemia. However, 
as the growth of Y. enterocolitica increased in the presence 
of Desferal, DFP should be prescribed instead of Desferal. 
Future studies are recommended to investigate various 
bacteria and antibiotic-resistant strains as well as chelators 
at various doses with regard to bacterial growth.
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